冠状动脉旁路移植术中使用大隐静脉桥对生存的影响:一项大型队列研究
基于澳大利亚与新西兰心胸外科医师学会2001—2013年数据库,纳入51 113例首次冠状动脉手术患者并链接国家死亡登记。与不使用大隐静脉桥相比,使用大隐静脉桥与全因死亡风险升高独立相关,倾向性评分匹配后结果一致。
要点
- 使用大隐静脉桥(SVG≥1)与不使用大隐静脉桥相比,未匹配死亡HR 1.24(95%CI 1.18-1.30),P<0.001。
- 倾向性评分匹配后,SVG≥1组死亡HR 1.22(95%CI 1.15-1.30),P<0.001。
- 在限定移植血管数量的匹配分析中,随大隐静脉桥使用数量增加,死亡HR升高。
核心结论
- 任何使用大隐静脉桥均与冠状动脉旁路移植术后生存率降低独立相关。
研究设计与样本
- 研究数据取自澳大利亚与新西兰心胸外科医师学会数据库2001—2013年记录,链接澳大利亚健康与福利研究所国家死亡登记,随访截止日期为2014年10月7日,分析全因死亡。
- 共纳入51 113例首次冠状动脉手术患者,按是否使用大隐静脉桥而非动脉桥分组,比较SVG≥1或SVG=1与SVG=0,并在3、4或5支移植血管组中分析随大隐静脉桥数量增加死亡风险的变化。
- 采用倾向性评分匹配分析,匹配变量为24个。
主要发现
- 未匹配分析中,SVG≥1组n=33 359,随访至12.5年生存率显著低于SVG=0组,死亡HR 1.24(95%CI 1.18-1.30),P<0.001。
- 未匹配分析中,SVG=1组死亡HR 1.19(95%CI 1.12-1.26),P<0.001。
- 倾向性评分匹配后,SVG≥1组n=14 355对,死亡HR 1.22(95%CI 1.15-1.30),P<0.001;SVG=1组n=12 316对,死亡HR 1.22(95%CI 1.14-1.30),P<0.001。
- 在限定移植血管数量的所有匹配分析中,随大隐静脉桥使用数量增加,死亡HR升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Saphenous vein graft (SVG) remains the predominant conduit used in coronary surgery. The internal mammary artery has higher later term patency and confers superior survival. Current debate focuses on the increased use of arterial conduits rather than eradication of venous conduits. METHODS: Patient data extracted from the Australian and New Zealand Society of Cardiothoracic Surgeons database from 2001-2013 were linked to the national death registry held by the Australian Institute of Health and Welfare for all-cause mortality with censor date 7 October 2014. The dataset was divided according to use of SVG rather than the arterial conduit. Analyses of SVG ≥ 1 or SVG = 1 were compared to SVG = 0. Additionally, groups of 3, 4 or 5 grafts were subjected to multiple analyses testing the mortality hazard with increasing use of SVG. Propensity score matched analyses were conducted using 24 variables. RESULTS: Of 51 113 primary coronary surgery patients, unmatched survival at up to 12.5 years was significantly lower for SVG ≥ 1, n = 33 359, mortality hazard ratio (HR) 1.24 [95% confidence interval (CI) 1.18-1.30], P < 0.001; and for SVG = 1, mortality HR 1.19 (95% CI 1.12-1.26), P < 0.001. Similar results were present for the propensity score matched groups; SVG ≥ 1, n = 14 355 pairs, HR 1.22 (95% CI 1.15-1.30), P < 0.001; and for SVG = 1, n = 12 316 pairs, HR 1.22 (95% CI 1.14-1.30), P < 0.001. All matched analyses within restricted graft groups had increasing HR with increased number of SVG used. CONCLUSIONS: Any use of SVGs is independently associated with reduced survival after coronary artery bypass surgery.
引用
- Royse A, Pawanis Z, Canty D, et al. The effect on survival from the use of a saphenous vein graft during coronary bypass surgery: a large cohort study. Eur J Cardiothorac Surg. 2018. PMID: 29893823. doi:10.1093/ejcts/ezy213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。